Skip to main content

SPRUCE BIOSCIENCES INC

For the period ended Mar 31, 2024. Filed May 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

SPRB$49.34+6.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Additional · Accumulated Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
SharesAmountCapitalGain/(Loss)DeficitEquity
Balance as of January 1, 202441,029,832$4$273,737$—$(197,232)$76,509
Exercise of common stock options120,328—180——180
Issuance of common stock related to vesting of restricted stock units, net of tax withholdings4,639—(2)——(2)
Stock-based compensation——1,562——1,562
Net loss————(11,625)(11,625)
Balance as of March 31, 202441,154,799$4$275,477$—$(208,857)$66,624
Additional · Accumulated Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
SharesAmountCapitalGain/(Loss)DeficitEquity
Balance as of January 1, 202323,601,004$3$218,354$(558)$(149,313)$68,486
Issuance of common stock related to vesting of restricted stock units, net of tax withholdings29,112—(23)——(23)
Issuance of common stock and warrants, net of offering costs of $2,72116,116,000150,894——50,895
Stock-based compensation——1,060——1,060
Unrealized gain on available for sale securities———370—370
Net loss————(12,791)(12,791)
Balance as of March 31, 202339,746,116$4$270,285$(188)$(162,104)$107,997
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.